Basilea Pharmaceutica AG (BSLN) — Long-term Investment Intensity
Basilea Pharmaceutica AG (BSLN) has a Long-term Investment Intensity of 13.5% as of December 2019. Long-term investments of CHF30.00 Million represent 13.5% of total assets of CHF221.47 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check BSLN total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Basilea Pharmaceutica AG Long-term Investment Intensity (2016–2019)
This chart shows how Basilea Pharmaceutica AG's Long-term Investment Intensity has evolved across 3 annual periods from 2016 to 2019. As of December 2019, the intensity stands at 13.5%, reflecting long-term investments of CHF30.00 Million against total assets of CHF221.47 Million CHF. Explore cash flow to debt ratio of Basilea Pharmaceutica AG to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for Basilea Pharmaceutica AG (2016–2019)
The table below presents the year-by-year Long-term Investment Intensity for Basilea Pharmaceutica AG from 2016 to 2019, covering 3 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see Basilea Pharmaceutica AG market cap and net worth.
| Year | LT Investment Intensity | LT Investments (CHF) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2019 | 13.5% | CHF30.00 Million | CHF221.47 Million | ▼ -0.7 pp |
| 2017 | 14.2% | CHF50.00 Million | CHF351.17 Million | ▼ -1.0 pp |
| 2016 | 15.3% | CHF50.00 Million | CHF327.76 Million | — |